Business
AlloVir to Participate in the SVB Securities Global Biopharma Conference
WALTHAM, Mass.--(BUSINESS WIRE)-- AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage, allogeneic T-cell immunotherapy company, today announced that Chief
About this update from Kalaris Therapeutics, Inc.
[{"type":"text","content":" WALTHAM, Mass.--(BUSINESS WIRE)--\nAlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage, allogeneic T-cell immunotherapy company, today announced that Chief Executive Officer Diana Brainard, M.D., will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 10:00 a.m. ET.\n\nA live webcast and archived replay of the fireside chat will be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com.\n\nAbout AlloVir\n\nAlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information, visit www.allovir.com or follow us on Twitter or LinkedIn.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230201005346/en/\n\nMedia and Investor:\nSonia Choi\nAlloVir\[email protected]\n\nSource: AlloVir, Inc.","length":3746,"tagName":"div"}]